Abstract
Cardiovascular (CV) events following commencement of cancer treatment are becoming increasingly recognised. The extent to which baseline CV factors influence the onset of major adverse cardiovascular events (MACE) in patients treated with non-anthracycline chemotherapy is not well characterised. The aim of our study was to examine the association between baseline cardiovascular risk factors and early and late complications of non-anthracycline chemotherapy.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
